Regeneron Pharmaceuticals insiders traded shares on November 3 and 4
On November 3 and 4, 2026, Regeneron Pharmaceuticals insiders reported option exercises, share sales, and gifts. Director Huda Y. Zoghbi and vice president and controller Jason Pitofsky exercised options and sold shares, while co-chief scientific officer Andrew J. Murphy gifted shares.
Key points
- On November 3, 2026, director Huda Y. Zoghbi exercised options for 7,439 shares worth $2,833,887.05.
- Co-chief scientific officer Andrew J. Murphy gifted 1,054 shares on November 3, 2026.
- The filed forms do not indicate the use of a Rule 10b5-1 trading plan, a preset selling schedule executives set up in advance.
Director and executive transactions
On November 3, 2026, director Huda Y. Zoghbi exercised options for 7,439 shares worth $2,833,887.05. That same day, she sold 7,439 shares for a total of $7,219,274.38.
On November 4, 2026, vice president and controller Jason Pitofsky exercised options for 3,883 shares worth $2,487,685.12. He also sold 4,062 shares for a total of $3,827,159.46.
Value of shares sold
Other events
Co-chief scientific officer Andrew J. Murphy gifted 1,054 shares on November 3, 2026.
Cautionary note on selling plans
The filed forms do not indicate the use of a Rule 10b5-1 trading plan, a preset selling schedule executives set up in advance. This neither confirms nor denies the existence of such a schedule, so insider motives for the trade dates remain unknown.
Next steps for shareholders
Investors should monitor future insider transaction reports published after any change in executive ownership.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Regeneron Pharmaceuticals
A notification in your browser or on your phone when we publish about Regeneron Pharmaceuticals. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
